Sandoz receives FDA approval for first and only denosumab biosimilars
05 mars 2024 13h24 HE
|
Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
04 mars 2024 01h00 HE
|
Sandoz Group
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team...
Biosimilars Market is Projected to Surpass USD 85 billion by 2031, Growing at CAGR 15.5%- Report by Transparency Market Research, Inc.
15 févr. 2024 09h35 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global biosimilars market is estimated to flourish at a CAGR of 15.5% from 2022 to...
Biologics Contract Development & Manufacturing Organization Market revenue to hit USD 39 Billion by 2036, says Research Nester
08 févr. 2024 05h30 HE
|
Research Nester
New York, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics contract development & manufacturing organization (CDMO) market size is projected to grow at a CAGR of over ~12% from 2024 to...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
22 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**...
Microbial Fermentation Technology Market revenue to hit USD 63 Billion by 2036, says Research Nester
06 déc. 2023 06h00 HE
|
Research Nester
New York , Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global microbial fermentation technology market size is expected to expand at 6% CAGR from 2024 to 2036. The market is anticipated to garner a...
Biosimilars Market To Reach USD 143.7 Billion By 2032 Report By DataHorizzon Research
18 oct. 2023 08h00 HE
|
DataHorizzon Research
Fort Collins, Colorado, Oct. 18, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, the Biosimilars Market size was valued at USD 27.7 Billion in 2022 and is expected to have a market size...
Biosimilars Market is Expected to Reach USD 1,26,019.67 Million By 2032
17 août 2023 11h00 HE
|
Precedence Research
Ottawa, Aug. 17, 2023 (GLOBE NEWSWIRE) -- The global biosimilars market revenue is projected to reach around USD 76,920.96 million by 2029, a study published by Towards Healthcare a sister firm of...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
03 juil. 2023 08h30 HE
|
Coherus BioSciences, Inc.
–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and...